Reimagining Global Biotech Leadership

In a world where the future of work is increasingly borderless, Lady Mireille Gillings, PhD, Hon DSc, offers a masterclass in leading with cultural dexterity, scientific precision, and human connection. As Founder and Executive Chair of HUYABIO International, she has built more than just a biotech company with dual headquarters in San Diego and Shanghai. She has orchestrated a living, breathing experiment in what it means to lead high-stakes innovation across continents.

The result? A company that not only thrives on the cutting edge of oncology therapeutics, but also sets the pace for how global teams can succeed through trust, adaptability, and purpose-driven collaboration.

Building a Cultural Bridge in Biotech 

When Gillings founded HUYABIO, she saw an unmet opportunity: to harness China’s rich pipeline of early-stage biotech discoveries and channel them into the regulatory and commercial ecosystems of global markets. What she quickly learned, however, was that success would hinge not just on science, but on the ability to align divergent business philosophies.

“The U.S. tends to favor fast decision-making and individual accountability, while China places a strong emphasis on relationship-building and consensus,” she explains. “Neither is better or worse, but you have to respect the difference.”

Rather than imposing one system on another, Gillings created a hybrid model. HUYABIO combines China’s speed and volume in drug discovery with the U.S.’s depth in regulatory strategy and commercialization. This dual strength allowed the company to bring HBI-8000, an oncology therapy, to market more efficiently than would have been possible within a single jurisdiction.

The linchpin of this model? Trust. “Technology keeps us connected, but real relationships are built in person,” she emphasizes. Regular face-to-face interactions, whether in boardrooms or over dinner, are a hallmark of her leadership.

Leading Through Autonomy, Not Control 

For many executives, managing teams across China, the U.S., and Japan might conjure visions of endless late-night calls and fragmented priorities. Gillings lived that reality early on. But she came to a pivotal realization: empowerment trumps oversight.

“You can’t be involved in every decision when teams span time zones,” she says. “You have to trust your people while ensuring alignment on strategic goals.”

That philosophy is baked into HUYABIO’s structure. Local teams are equipped with decision-making authority and connected through shared priorities and frameworks. This distributed model has the added benefit of constant momentum. “While one team winds down for the day, another is just starting. We’re moving projects forward 24/7.”

Even more powerful is the exchange of perspectives. When HUYABIO refined its oncology strategy, it was the fusion of China’s agile clinical trial process with the U.S.’s rigorous regulatory insights that unlocked true innovation. It’s a reminder that diversity isn’t just an HR metric – it’s a competitive advantage.

Innovation Through Inclusion and Intentionality 

If autonomy and alignment are the structural pillars of HUYABIO, then inclusivity is its cultural core. Gillings fosters an environment where innovation doesn’t hinge on hierarchy but on psychological safety.

“Innovation happens when people feel safe to challenge ideas,” she notes. That requires cultural fluency. In direct communication cultures, speed and candor drive progress. In others, feedback must be more nuanced. Gillings bridges this by tailoring meeting formats and follow-ups to ensure all voices are heard.

She also invests in connection beyond the confines of Zoom. Scientific exchange programs, industry events, and anniversary celebrations bring people together across borders. “Some of our best collaborations started over coffee, not PowerPoint,” she says. It’s a simple truth too often overlooked: breakthroughs happen when people feel seen and valued.

Continuous learning is another strategic imperative. HUYABIO encourages staff to engage in global scientific forums, regulatory updates, and leadership development. The pace of biotech is unforgiving – those who don’t evolve fall behind. “The most valuable insights often come when you step outside your usual environment,” Gillings says.

How Cognitive Biases Can Disrupt—or Drive—Global Collaboration 

Even the most sophisticated leaders are not immune to cognitive bias. In the high-stakes world of global biotech, these unconscious patterns can either hinder innovation or, when recognized and addressed, be transformed into drivers of deeper understanding and smarter decisions.

Take the status quo bias, for example – the tendency to prefer familiar systems over potentially superior alternatives. In cross-border collaborations, this can manifest when teams resist adopting unfamiliar processes or methodologies from other regions. Without awareness, a U.S.-based team might default to FDA-aligned processes and overlook faster, ethically sound clinical trial models from China. At HUYABIO, Gillings has actively worked against this inertia. Her dual-market strategy forced all sides to question long-held assumptions and remain open to reinvention. “The key is to define guardrails but not dictate every detail,” she says – a direct counter to the pull of the status quo.

Another deeply relevant force is confirmation bias, where individuals interpret information in ways that affirm their pre-existing beliefs. This can introduce hidden risks in multicultural teams, where leaders may unconsciously favor strategies that align with their home-market norms. A U.S. executive might discount a Chinese colleague’s collaborative approach as inefficient, while a Chinese executive might misread direct feedback as disrespectful. Gillings mitigates this by creating intentional spaces for cross-cultural dialogue. Her emphasis on face-to-face interaction and scientific exchange ensures that different perspectives are not just tolerated, but celebrated. When teams come together around a shared scientific mission, it becomes harder for confirmation bias to calcify into siloed thinking.

By recognizing these biases—and designing systems that actively counter them – HUYABIO has managed to turn potential blind spots into a source of strength. In doing so, it offers a powerful blueprint for how global organizations can move from cultural collision to collaborative innovation.

Designing the Future of Global Work 

For all the sophistication of HUYABIO’s technology stack – real-time data sharing, collaborative platforms, asynchronous workflows – Gillings is quick to remind us that tools are not substitutes for intentional leadership. “Just because people use the same tools doesn’t mean they’re aligned. That takes strategy and heart.”

She believes the future of work will be both more global and more relationship-driven. The companies that succeed won’t just master cross-border logistics. They’ll cultivate cultures where people “think together, not just work together.”

That future also requires navigating the tension between standardization and local relevance. HUYABIO centralizes processes where quality demands it—such as clinical protocols and compliance – but adapts operations, hiring, and leadership styles to regional norms. “We define the guardrails, but we don’t dictate every detail,” she says.

Perhaps most critically, Gillings sees science itself as the unifier. Across languages, borders, and business norms, HUYABIO’s teams are united by a singular mission: accelerating life-saving treatments for patients. That shared purpose transcends difference and fosters inclusivity not through mandates, but meaning.

Have you read?
The World’s Best Medical Schools.
The World’s Best Universities.
The World’s Best International High Schools.
The World’s Best Business Schools.
The World’s Best Fashion Schools.
The World’s Best Hospitality And Hotel Management Schools.